Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 178-183

  Seeman, Philip ^a,b   Tinazzi, Michele ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Caudate nucleus; Dopamine supersensitivity; Putamen; Striatum

Indexed keywords

4 [4 CHLOROPHENYL] 1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL]PYRIDINIUM ION; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; CYTOCHROME P450 1A2; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; GLYCINE; HALOPERIDOL; HEAT SHOCK PROTEIN; NEUROLEPTIC AGENT; NEUROMELANIN; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERINE; THIORIDAZINE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AGE; BRADYKINESIA; CELL DENSITY; CELL LOSS; DAT1 GENE; DOPAMINE D3 RECEPTOR GENE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; DYSKINESIA; GABA GENE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; GL12 GENE; HSPG2 GENE; HUMAN; IN VIVO STUDY; LONG TERM CARE; MORTALITY; MUSCLE RIGIDITY; NERVE CELL DEGENERATION; NERVE ENDING; NONHUMAN; ORAL DYSKINESIA; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SLC6A3 GENE; SUBSTANTIA NIGRA; TAQ1A GENE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREMOR; ZNF202 GENE;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINERGIC NEURONS; HUMANS; MOVEMENT DISORDERS; SCHIZOPHRENIA;

EID: 84875250494     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.011     Document Type: Review

References (52)

1. Aberg K., Adkins D.E., Bukszár J., Webb B.T., Caroff S.N., Miller D.D., et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010, 67(3):279-282.
2. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008, 13(5):544-556.
3. Chen S., Seeman P., Liu F. Antipsychotic drug binding in the substantia nigra: an examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and multiple sclerosis patients, and its relation to tardive dyskinesia. Synapse 2011, 65(2):119-124.
4. Christensen E., Moller J.E., Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 1970, 46:14-23.
5. Ezrin-Waters C., Seeman M.V., Seeman P. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables. J Clin Psychiatry 1981, 42:16-22.
6. Fischman A.J., Bonab A.A., Babich J.W., Palmer E.P., Alpert N.M., Elmaleh D.R., et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998, 29(2):128-141.
7. Friedman J.H. Managing idiopathic Parkinson's disease in patients with schizophrenic disorders. Parkinsonism Relat Disord 2011, 17(3):198-200.
8. Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull 2013, 39(1):22-32.
9. Gadit A. Schizophrenia and Parkinson's disease: challenges in management. BMJ Case Rep 2011, [Dec 20].
10. Ganzini L., Casey D.E., Hoffman W.F., McCall A.L. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153(12):1469-1475.
11. Greenbaum L., Alkelai A., Rigbi A., Kohn Y., Lerer B. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 2010, 25(16):2809-2817.
12. Greenbaum L., Alkelai A., Zozulinsky P., Kohn Y., Lerer B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2011, [Aug 2]. 10.1038/tpj.2011.32.
13. Habermeyer B., Kneifel S., Lotz-Bläuer I., Müller-Spahn F. Psychosis in a case of schizophrenia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2008, 20(3):373-375.
14. Hornykiewicz O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis 2008, 5(3-4):114-117.
15. Hsiao M.C., Lin K.J., Liu C.Y., Tzen K.Y., Yen T.C. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 2003, 65(1):39-46.
16. Ishibashi K., Ishii K., Oda K., Kawasaki K., Mizusawa H., Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 2009, 63(4):282-290.
17. Jellinger K. Neuropathologic findings after neuroleptic long-term therapy. Neurotoxicology 1977, 25-42. Raven Press, New York. L. Roizin, H. Shiraki, N. Grcevic (Eds.).
18. Kane J.M. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004, 65:16-20.
19. +. Neurotox Res 2004, 6(7-8):535-542.
20. Kenney C., Hunter C., Davidson A., Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008, 48:379-384. [2008].
21. Laakso A., Vilkman H., Alakare B., Haaparanta M., Bergman J., Solin O., et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 2000, 157(2):269-271.
22. Laakso A., Bergman J., Haaparanta M., Vilkman H., Solin O., Syvälahti E., et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001, 52(1-2):115-120.
23. Lai T.K.Y., Seeman P., Liu F. Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia. Synapse 2011, 66:273-276.
24. Lan C.C., Su T.P., Chen Y.S., Bai Y.M. Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson's disease. Gen Hosp Psychiatry 2011, 33(4):411. [e3-5].
25. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000, 20(3):423-451.
26. 123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000, 27(3):346-349.
27. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000, 27(7):867-869.
28. Lavalaye J., Sarlet A., Booij J., Linszen D.H., Reneman L., Gersons B.P., et al. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology (Berl) 2001, 155(1):107-109.
29. 123]FP-CIT SPECT. Schizophr Res 2001, 47(1):59-67.
30. Lee H.J., Kang S.G. Genetics of tardive dyskinesia. Int Rev Neurobiol 2011, 98:231-264.
31. 123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 2005, 181(2):401-406.
32. Mateos J.J., Lomeña F., Parellada E., Mireia F., Fernandez-Egea E., Pavia J., et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 2007, 191(3):805-811.
33. Miller L.G., Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989, 149(11):2486-2492.
34. Nieuwenhuys R., Voogd J., Van Huijzen C. The human central nervous system 2008, 206. Springer Berlin, Heidelberg, [pp. 967]. 4th ed.
35. 123I-FP-CIT binding to the dopamine transporter in the rat striatum: an in vivo imaging study with a dedicated small-animal SPECT camera. J Nucl Med 2009, 50(7):1147-1152.
36. Park Y.M., Kang S.G., Choi J.E., Kim Y.K., Kim S.H., Park J.Y., et al. No evidence for an association between dopamine D2 receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig 2011, 8(1):49-54.
37. Rajput A.H., Sitte H.H., Rajput A., Fenton M.E., Pifl C., Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008, 70(16 Pt 2):1403-1410.
38. Schmitt G.J., Dresel S., Frodl T., la Fougère C., Boerner R., Hahn K., et al. Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 2012, 262(3):183-191.
39. Seeman P. The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 1972, 24(4):583-655.
40. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988, 8(4 Suppl.):3S-9S.
41. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10:515-531.
42. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989, 3:96-97.
43. 123I]FP-CIT single photon emission computed tomography findings in drug-induced parkinsonism. Schizophr Res 2012, 139(1-3):40-45.
44. Tousimis A.J., Barron C.N. Chlorpromazine and the eye of the dog. An electron microscopic study. Exp Mol Pathol 1970, 13(1):89-110.
45. Troiano A.R., Schulzer M., de la Fuente-Fernandez R., Mak E., McKenzie J., Sossi V., et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 2010, 64(2):146-151.
46. Van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Zoghbi S.S., Baldwin R.M., et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002, 10(1):36-43.
47. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., et al. Dopamine transporters decrease with age. J Nucl Med 1996, 37(4):554-559.
48. Woods S.W., Morgenstern H., Saksa J.R., Walsh B.C., Sullivan M.C., Money R., et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010, 71:463-474.
49. Yang Y.K., Yu L., Yeh T.L., Chiu N.T., Chen P.S., Lee I.H. SPECT study. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 2004, 161(8):1496-1498.
50. Yoder K.K., Hutchins G.D., Morris E.D., Brashear A., Wang C., Shekhar A. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 2004, 71(2-3):371-375.
51. Zai C.C., Hwang R.W., De Luca V., Müller D.J., King N., Zai G.C., et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007, 10(5):639-651.
52. Zai C.C., De Luca V., Hwang R.W., Voineskos A., Müller D.J., Remington G., et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007, 12(9):794-795.